CommercialCoverageMedium impact
Uveitis
Blue Cross & Blue Shield of Mississippi·MS · Ophthalmology·Medical Policy
Effective date
Jan 1, 2025
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their uveitis policy effective January 1, 2025, restricting adalimumab coverage to only Hadlima and Simlandi while removing coverage for 9 other adalimumab products including Humira. Prior authorization remains required for all covered adalimumab products used to treat non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
Action Required
Immediately: Update billing system and provider alerts to reflect that only Hadlima (adalimumab-bwwd) and Simlandi (adalimumab-ryvk) are covered adalimumab options for uveitis treatment effective January 1, 2025. Notify ophthalmologists that Humira and 8 other adalimumab biosimilars are no longer covered by BCBS Mississippi. Continue requiring prior authorization for all adalimumab products. Claims for non-covered adalimumab products will be denied.